HOME >> MEDICINE >> NEWS
Data showed improved quality of life and patient satisfaction with SYMBICORT

Wilmington, DE May 22, 2007 New data demonstrated that the combination asthma therapy, SYMBICORT (budesonide/formoterol fumarate dihydrate), led to significant improvements in health-related quality of life (HRQL) and greater patient-reported satisfaction with asthma treatment, versus its monocomponents (budesonide or formoterol) or placebo. The results from these two 12-week randomized, double-blind trials were presented at the American Thoracic Society (ATS) 2007 International Conference held in San Francisco, May 18-23.

"Asthma is a chronic disease that can have a significant effect on patients' day-to-day routine, including participating in activities, such as walking to the store or even playing with their children," said Dr. Kevin R. Murphy, Clinical Professor, University of Nebraska Medical Center. "For the millions of asthma sufferers in the U.S., and especially for those whose condition is not adequately controlled with their current medication, SYMBICORT will provide a new option for patients to help manage and control their asthma, allowing them to get back to their daily activities."

SYMBICORT is a recently approved, combination therapy indicated for the long-term maintenance treatment of asthma in patients 12 years of age and older. SYMBICORT does not replace fast-acting inhalers and should not be used to treat acute symptoms of asthma. Studies of patients treated with SYMBICORT demonstrated clinically significant improvement in lung function occurring within 15 minutes of beginning treatment. SYMBICORT has safety data in long-term studies of up to one year, and has a robust cardiac safety profile.

"The studies presented at this year's ATS conference provided valuable data on asthma control and asthma-related quality of life with SYMBICORT," said Chris O'Brien, Senior Director, Medical Science, AstraZeneca. "Asthma sufferers will have a new, rapid-acting combination treatment to help them achieve asthma control."

Administere
'"/>

Contact: Tracy Knudsen
Tracy.Knudsen@astrazeneca.com
302-885-1933
AstraZeneca
22-May-2007


Page: 1 2 3

Related medicine news :

1. New analysis showed UC patients in clinical remission had higher rates of employment
2. ROZEREM (ramelteon) showed significant reduction in time to fall asleep
3. New study showed ramelteon helped adults with chronic insomnia fall asleep, sleep longer
4. LSUHSC awarded designation resulting in improved patient safety and outcomes
5. ACP supports improved access to information on relative strengths and weaknesses
6. Performance-related financial incentives for hospitals not linked with improved quality of care
7. Investigational nonstimulant Guanfacine XR significantly improved child, adolescent ADHD symptoms
8. Alzheimers weight gain initiative also improved patients intellectual abilities
9. Acute coronary syndrome therapy improvements linked with fewer deaths and improved clinical outcomes
10. New study reports improved treatment and reduced mortality for patients with heart failure
11. Lymph node evaluation linked to improved survival for colon cancer patients

Post Your Comments:
(Date:8/28/2015)... Florida (PRWEB) , ... August 28, 2015 , ... ... holistic approach to medicine through health promotion and disease prevention, improving a patient’s ... most prevalent diseases in the community, including heart disease, cancer, diabetes, HIV/AIDS, STDs, ...
(Date:8/27/2015)... ... August 28, 2015 , ... Best-selling Author Vanessa Diffenbaugh, ... through “The Language of Flowers,” has joined the Youth Villages national board of ... YVLifeSet program, was piqued by her passion for helping foster youth. Her debut ...
(Date:8/27/2015)... ... 27, 2015 , ... Keck Graduate Institute (KGI), School of Pharmacy celebrated its ... a formal ceremony recognizing them as members of the 2nd class of the KGI ... Symbolizing dedication to clinical service and patient care, the White Coat Ceremony is held ...
(Date:8/27/2015)... Los Anegeles and Costa Mesa, CA (PRWEB) , ... August 27, ... ... revolving door, going in to get help, leaving weeks or months later, relapsing and ... by overdose or accidents under the influence while in sober living homes or soon ...
(Date:8/27/2015)... ... August 27, 2015 , ... According to an article published ... Hernia Surgery involved many conversations between hernia experts surrounding the search for the ideal ... that many different experts have different ideas about which is the best mesh for ...
Breaking Medicine News(10 mins):Health News:Health Clinic Opening and Public Art Unveiling 2Health News:Best-selling Author Vanessa Diffenbaugh Joins Youth Villages National Board of Directors 2Health News:Best-selling Author Vanessa Diffenbaugh Joins Youth Villages National Board of Directors 3Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 2Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 3Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 4Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 2Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 3Health News:Recent Article on Hernia Mesh Developments Highlights Viable Options, But Shows a Need for Further Research, notes Dr. Shirin Towfigh 2
(Date:8/27/2015)... 2015  Mytrus, a technology and services company revolutionizing clinical trials, ... consent has received approval for use by ... the first time e-Consent technology will be used in ... Mytrus was also the first electronic informed ... by the U.S. Food and Drug Administration in 2011. ...
(Date:8/27/2015)... , Aug. 27, 2015  Lightwave Logic, ... the development of Next Generation Photonic Devices ... applications in high speed fiber-optic data communications and ... Lebby has been appointed to the Company,s ... in the field of optoelectronics is widely recognized ...
(Date:8/27/2015)... 2015 WuXi PharmaTech (Cayman) Inc. (NYSE:  WX), a ... company serving the pharmaceutical, biotechnology, and medical ... and manufacturing subsidiary Shanghai SynTheAll Pharmaceutical Co., ... the Japan PMDA for the manufacture of ... drug in July. STA is now the ...
Breaking Medicine Technology:Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3WuXi PharmaTech's STA Subsidiary Receives First Approval from Japanese Regulatory Authorities 2
Cached News: